PropThink: For AMRN, NCE Status May Be Moot Point Given New Patent Allowances
(Thomson Reuters ONE) -
Amarin Corp. (NASDAQ:AMRN) announced yesterday that the U.S. Patent and Trade
Office (PTO) issued a Notice of Allowance for Patent Application 13/282,145,
which was based on results from the Phase III MARINE trial (patients with very
high triglycerides). Additionally, on the PTO's website, it appears that two
other patent applications based on the MARINE trial (12/702,889 and 13/349,153)
have also been granted Notices of Allowance, which when issued, are expected to
protect Vascepa through 2030. These soon-to-be issued patents are very
important, and may mean that whether or not the FDA grants new chemical entity
(NCE) status for Vascepa is becoming a moot point. Patent protection out to
2030 is far more important than the 5 year regulatory exclusivity offered by the
FDA (see PropThink's previous coverage), and as a result, AMRN may be in
position to secure a major drug company partnership or sell the company given
the improving intellectual property position around Vascepa. Regardless, the
next FDA Orange Book update is expected in mid-September, and if NCE status is
granted, this could take shares of AMRN up, given the weight that investors have
placed on this issue. Essentially, the risk around Vascepa's U.S. market
exclusivity is diminishing, which should continue to reflect in the rising price
of the stock.
To see this article at PropThink.com, click here.
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com. To learn
more visit us at http://www.propthink.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: PropThink via Thomson Reuters ONE
[HUG#1638868]
Unternehmensinformation / Kurzprofil:
Datum: 05.09.2012 - 14:37 Uhr
Sprache: Deutsch
News-ID 180533
Anzahl Zeichen: 2566
contact information:
Town:
New York
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 176 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PropThink: For AMRN, NCE Status May Be Moot Point Given New Patent Allowances"
steht unter der journalistisch-redaktionellen Verantwortung von
PropThink (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
